PLAUR and prostate carcinoma: Margheri et al. used an 18-mer ASO against uPAR known as “uPAR aODNs” that significantly reduced uPAR levels and subsequently decreased prostate cancer bone metastases when PC3 cells were injected into immunocompromised animals via intracardiac injections [88].